Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effects of Arzoxifene on Bone Mass and the Uterus
This study has been completed.
Sponsored by: Eli Lilly and Company
Information provided by: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT00085956
  Purpose

The purposes of this study are to determine:

  • The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women.
  • The effects of arzoxifene on the uterus (womb) in postmenopausal women.
  • The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density.
  • The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk.
  • The safety of arzoxifene and any side effects that might be associated with its use.

Condition Intervention Phase
Postmenopausal Bone Loss
 Drug: Arzoxifene
Drug: Placebo
 Phase III

MedlinePlus related topics: Heart Disease in Women Heart Diseases Minerals
Drug Information available for: Arzoxifene
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Effects of Arzoxifene on Bone Mineral Density and Endometrial Histology in Postmenopausal Women.

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women
  • The effects of arzoxifene on the uterus (womb) in post menopausal women
  • The safety of arzoxifene and any side effects that might be associated with its use

Secondary Outcome Measures:
  • The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density
  • The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease
  • The effects of arzoxifene on breast density

Estimated Enrollment: 300
Study Start Date: April 2004
Estimated Study Completion Date: February 2007
  Eligibility

Ages Eligible for Study:   45 Years to 60 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Female
  • 45 to 60 years of age, inclusive
  • At least 2 years since last menstrual cycle
  • Intact uterus (womb).

Exclusion Criteria:

  • Existing fracture of the spine.
  • Bone disorders, other than low bone mass
  • History of cancer in the last 5 years. Also, any history, at any time, of breast cancer or cancer of the lining of the uterus.
  • Abnormal or unexplained vaginal bleeding.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00085956

Locations
United States, California
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
San Diego, California, United States, 92103
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Lilly Clinical Trial Registry  This link exits the ClinicalTrials.gov site

Study ID Numbers: 8537, H4Z-MC-GJAE
Study First Received: June 18, 2004
Last Updated: March 7, 2007
ClinicalTrials.gov Identifier: NCT00085956  
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Musculoskeletal Diseases
Osteoporosis, Postmenopausal
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases

ClinicalTrials.gov processed this record on January 16, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services